Treatment response and its predictors of immunosuppressive therapy in patients with severe or very severe aplastic anemia

Thanakrit Somprasertkul , Weerayaporn Trirattanapikul , Sittichai Khamsai , Verajit Chotmongkol , Kittisak Sawanyawisuth
{"title":"Treatment response and its predictors of immunosuppressive therapy in patients with severe or very severe aplastic anemia","authors":"Thanakrit Somprasertkul ,&nbsp;Weerayaporn Trirattanapikul ,&nbsp;Sittichai Khamsai ,&nbsp;Verajit Chotmongkol ,&nbsp;Kittisak Sawanyawisuth","doi":"10.1016/j.medidd.2024.100181","DOIUrl":null,"url":null,"abstract":"<div><p>Severe aplastic anemia (SAA) is a hematological condition with high morbidity and mortality. Treatment with immunosuppressive agents is alternative treatment if bone marrow transplant is not available. Several studies reported predictors of successful treatment in patients with SAA. However, the results are not consistent and not specific to anti-thymocyte globulin and cyclosporine. This study aimed to evaluate the predictor of response to treatment in this specific regimen. This study was a retrospective cohort study. The inclusion criteria were adult patients with SAA or very SAA who received this regimen. Clinical factors predictive of response to treatment were computed. There were 92 patients met the study criteria. Of those, 56 patients (60.87%) were in a group of response to treatment. There were nine factors in the predictive model for good response to treatment. Only body mass index was independently associated with response to treatment with an adjusted odds ratio of 1.31 (95% confidence interval of 1.04, 1.67). Age or hematological laboratory factors such as lymphocyte or neutrophil count were not significant. Low body mass index may be less likely to response to immunosuppressive treatment in patients with severe or very severe aplastic anemia.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"22 ","pages":"Article 100181"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259009862400006X/pdfft?md5=c7cc3102353ae4f94e197711f5758dd4&pid=1-s2.0-S259009862400006X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine in Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S259009862400006X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Severe aplastic anemia (SAA) is a hematological condition with high morbidity and mortality. Treatment with immunosuppressive agents is alternative treatment if bone marrow transplant is not available. Several studies reported predictors of successful treatment in patients with SAA. However, the results are not consistent and not specific to anti-thymocyte globulin and cyclosporine. This study aimed to evaluate the predictor of response to treatment in this specific regimen. This study was a retrospective cohort study. The inclusion criteria were adult patients with SAA or very SAA who received this regimen. Clinical factors predictive of response to treatment were computed. There were 92 patients met the study criteria. Of those, 56 patients (60.87%) were in a group of response to treatment. There were nine factors in the predictive model for good response to treatment. Only body mass index was independently associated with response to treatment with an adjusted odds ratio of 1.31 (95% confidence interval of 1.04, 1.67). Age or hematological laboratory factors such as lymphocyte or neutrophil count were not significant. Low body mass index may be less likely to response to immunosuppressive treatment in patients with severe or very severe aplastic anemia.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
重度或极重度再生障碍性贫血患者对免疫抑制疗法的治疗反应及其预测因素
重型再生障碍性贫血(SAA)是一种发病率和死亡率都很高的血液病。在无法进行骨髓移植的情况下,使用免疫抑制剂是一种替代治疗方法。一些研究报告了再生障碍性贫血患者成功治疗的预测因素。然而,研究结果并不一致,也没有针对抗胸腺细胞球蛋白和环孢素的特异性研究。本研究旨在评估这种特殊疗法的治疗反应预测因素。本研究是一项回顾性队列研究。纳入标准为接受该疗法的 SAA 或极 SAA 成年患者。对预测治疗反应的临床因素进行了计算。共有 92 名患者符合研究标准。其中,56 名患者(60.87%)对治疗有反应。治疗反应良好的预测模型中有九个因素。只有体重指数与治疗反应独立相关,调整后的几率比为 1.31(95% 置信区间为 1.04,1.67)。年龄或血液实验室因素(如淋巴细胞或中性粒细胞计数)并不重要。体重指数低可能会降低重度或极重度再生障碍性贫血患者对免疫抑制治疗的反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medicine in Drug Discovery
Medicine in Drug Discovery Medicine-Pharmacology (medical)
CiteScore
8.30
自引率
0.00%
发文量
30
审稿时长
21 days
期刊介绍:
期刊最新文献
Recent approaches in nanotoxicity assessment for drug delivery applications: Challenges and prospects Structural features of arrestin-mediated GPCR signaling The distribution of Hypocretin/Orexin receptor mRNA in the mouse and human brain Targeting BCL-2 family proteins using BH3 mimetic drugs for cancer therapy: A systematic review of randomized clinical trials Pharmacological effects of dragon’s blood from Dranaena cochinchinensis (Lour.) S.C. Chen and its application in cardiovascular diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1